KKR to Acquire Integer Holdings in $5.7 Billion Deal Following Strategic Review
Integer Holdings (NYSE: ITGR) agreed to be acquired by KKR in an all-cash deal valued at about $5.7 billion. Integer shareholders will receive $127 per share, a 51.8% premium to the April 29 close and 28.8% to the July 31 30-day VWAP. Expected close by end-2026, subject to approvals. ITGR withdrew guidance and will not hold its Q2 call.
How this was made
The 30-second read
Why it matters
The definitive agreement at a specified cash price is a direct catalyst for ITGR’s equity and any related options or deal-arb strategies, with the key trading variable shifting to approval and regulatory clearance risk.
Market read
Definitive, all-cash takeout terms with a large premium and no financing contingency make this a high-conviction, time-sensitive M&A catalyst for ITGR.
What to watch
ITGR withdrawing guidance and canceling the earnings call can reduce near-term fundamental information flow, making the stock more purely dependent on deal progress and approval timelines.
Background
Integer initiated a strategic review to evaluate alternatives, then selected KKR’s proposal after reviewing multiple options with advisers.
Ticker impact
Integer agreed to be acquired by KKR in an all-cash $5.7B deal at $127 per share, a 51.8% premium.
Likely continued strength and elevated deal-arb activity until shareholder/regulatory approvals; downside risk is deal spread widening on any execution or regulatory concerns.
The article provides definitive deal terms (cash price, EV, premium), states no financing contingency, and notes ITGR will withdraw guidance and stop its earnings call, all of which are directly tradable for deal-risk pricing.
Market effects
Reinforces consolidation interest in medical device CDMOs, potentially supporting valuation expectations for other outsourcing peers.
Primarily US-listed single-name impact, with limited direct regional spillover beyond healthcare manufacturing M&A sentiment.
Global manufacturing footprint and regulatory-driven outsourcing demand could keep cross-border strategic interest elevated in medtech services.
Counterpoint
Even with no financing contingency, deal spreads can widen on regulatory review or shareholder dissent, creating downside for those chasing the premium.
Key entities
- companyInteger Holdings Corp.
NYSE-listed medical device contract development and manufacturing organization being acquired for $5.7B in an all-cash deal.
- acquirerKKR
Private equity firm acquiring Integer and planning to invest in manufacturing capacity, innovation, and workforce programs.
- executivePayman Khales
Integer CEO quoted supporting the transaction as the next chapter for growth and innovation.
